The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
Chen
Junfa
J
Zheng
Zhiyin
Z
Shen
Jianping
J
Zhou
Yuhong
Y
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003108:Colonic Diseases / Q000139:chemically induced / Q000188:drug therapy*; D000069439:Dasatinib; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D010996:Pleural Effusion / Q000139:chemically induced / Q000188:drug therapy*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects*; D040521:Subcutaneous Tissue / Q000187:drug effects* / Q000473:pathology; D013844:Thiazoles / Q000009:adverse effects*; D013947:Thymosin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014456:Ulcer / Q000139:chemically induced / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D013947:Thymosin; D011505:Protein-Tyrosine Kinases; D000069439:Dasatinib; D008775:Methylprednisolone